Analysed SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) News Sources
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
15-04-2026
yahoo.com
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
22-04-2026
yahoo.com
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
29-04-2026
yahoo.com
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
05-05-2026
yahoo.com
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
12-05-2026
yahoo.com
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully
15-05-2026
yahoo.com
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
20-05-2026
yahoo.com
What is the current price of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The current price of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is $3.48.
SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) since the previous trading day is $0.04.
SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) since the previous trading day is 1.1628%.
What is the most recent average sentiment score for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The most recent average sentiment score for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The most recent sentiment for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is .
SEC-8K** Filing Available For SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.